Table 1.
Autophagy combination treatment strategies in leukemia. CLL = Chronic lymphocytic leukemia; CML = Chronic myeloid leukemia; AML = Acute myeloid leukemia; ALL = Acute lymphoblastic leukemia.
| Autophagy Modifier | Combination Strategy | Leukemia Types | Context | Ref |
|---|---|---|---|---|
| HCQ, Lys05, PIK-III (VPS34), Spautin-1, shATG4B, LV-320, NSC185058 | +TKIs | CML | In vitro and in vivo | [6,7,83,142,143] |
| CQ | +l-asp | ALL | In vitro and in vivo | [130] |
| CQ, siATG5 | +Tigecycline | CML | In vitro | [144] |
| HCQ | +NVP-BEZ235 | CML | In vitro and in vivo | [145] |
| HCQ, shATG7 | +Vismodegib | CML | In vitro | [146] |
| atg7−/− | +AraC | Murine AML | In vitro and in vivo | [121] |
| CQ, Bafilomycin A1, siMAP1LC3, siSQSTM1 | +Cytarabine | AML | In vitro | [147] |
| CQ, 3-MA, shATG7 | +AraC | AML | In vitro and in vivo | [54,148] |
| Bafilomycin A1, siBECN1 | +Statins | CLL, CML, AML, ALL | In vitro | [149] |
| − | shS100A8+adriamycin or vincristine | CML, AML, ALL | In vitro | [17] |
| CQ, 3-MA | +rhArginase | AML, ALL | In vitro | [150,151] |
| − | rhArginase+AraC or dexamethasone | CML, AML, ALL | In vitro and in vivo | [152,153] |